765 related articles for article (PubMed ID: 28750079)
1. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.
Romagnuolo R; Scipione CA; Boffa MB; Marcovina SM; Seidah NG; Koschinsky ML
J Biol Chem; 2015 May; 290(18):11649-62. PubMed ID: 25778403
[TBL] [Abstract][Full Text] [Related]
3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.
Raal FJ; Giugliano RP; Sabatine MS; Koren MJ; Blom D; Seidah NG; Honarpour N; Lira A; Xue A; Chiruvolu P; Jackson S; Di M; Peach M; Somaratne R; Wasserman SM; Scott R; Stein EA
J Lipid Res; 2016 Jun; 57(6):1086-96. PubMed ID: 27102113
[TBL] [Abstract][Full Text] [Related]
5. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
6. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 Association With Lipoprotein(a).
Tavori H; Christian D; Minnier J; Plubell D; Shapiro MD; Yeang C; Giunzioni I; Croyal M; Duell PB; Lambert G; Tsimikas S; Fazio S
Circ Res; 2016 Jun; 119(1):29-35. PubMed ID: 27121620
[TBL] [Abstract][Full Text] [Related]
8. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
[TBL] [Abstract][Full Text] [Related]
9. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
[TBL] [Abstract][Full Text] [Related]
10. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
Le QT; Blanchet M; Seidah NG; Labonté P
J Biol Chem; 2015 Sep; 290(38):23385-400. PubMed ID: 26195630
[TBL] [Abstract][Full Text] [Related]
11. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
12. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.
DeVay RM; Yamamoto L; Shelton DL; Liang H
PLoS One; 2015; 10(4):e0125127. PubMed ID: 25905719
[TBL] [Abstract][Full Text] [Related]
13. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
[TBL] [Abstract][Full Text] [Related]
14. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
15. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
[TBL] [Abstract][Full Text] [Related]
16. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
17. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
[TBL] [Abstract][Full Text] [Related]
18. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA
PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873
[TBL] [Abstract][Full Text] [Related]
19. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664
[TBL] [Abstract][Full Text] [Related]
20. Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor.
Topchiy E; Cirstea M; Kong HJ; Boyd JH; Wang Y; Russell JA; Walley KR
PLoS One; 2016; 11(5):e0155030. PubMed ID: 27171436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
